Which asthma therapy is a monoclonal antibody that inhibits IL-4 and IL-13 signaling?

The correct answer is dupilumab, which is a monoclonal antibody that specifically targets and inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling. These cytokines play a crucial role in the inflammatory pathways associated with asthma, particularly in patients who experience severe asthma exacerbations involving Type 2 inflammation. By blocking IL-4 and IL-13 signaling, dupilumab helps to reduce the inflammatory response and improve asthma control, leading to fewer exacerbations and improved lung function.

In contrast, reslizumab and mepolizumab do not block IL-4 or IL-13 directly; instead, they are monoclonal antibodies that target IL-5, which is involved in the growth, activation, and survival of eosinophils. These therapies are effective for treating eosinophilic asthma but do not address the IL-4 and IL-13 pathways directly.

Benralizumab also targets IL-5, similar to reslizumab and mepolizumab, but primarily works by depleting eosinophils through antibody-dependent cell-mediated cytotoxicity rather than inhibiting IL-4 or IL-13 signaling. Therefore, while all these therapies are used to